Quironsalud Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Quironsalud group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Quironsalud Group Today - Breaking & Trending Today

European Commission Approves Merck's KEYTRUDA® Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer

KEYTRUDA Is Now Approved in Combination With Chemotherapy as First-Line Treatment for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 and Who Have Not Received Prior Chemotherapy for Metastatic Disease KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From . ....

United States , Vicki Goodman , Peter Dannenbaum , Javier Cort , Melissa Moody , Quironsalud Group , Merck Research Laboratories , European Commission , Statement Of Merck Co Inc , Exchange Commission , Merck Co Inc , European Union , International Breast Cancer Center , Now Approved , First Line Treatment , Patients With Locally Recurrent Unresectable , Tumors Express , Metastatic Disease , These Patients , Results From , Combined Positive Score , Merck Research , European Approval , Neck Squamous Cell Cancer , Bladder Cancer , Bacillus Calmette Guerin Unresponsive ,